LKB1 loss is rarely detected in EGFR-mutant NSCLC (Koivunen et al., 2008; Gao et al., 2010), but metabolic reprogramming and redox imbalance nonetheless occur and contribute to EGFR TKI resistance (Wang et al., 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.